Clinical Trials Logo

Hemosiderosis clinical trials

View clinical trials related to Hemosiderosis.

Filter by:
  • Withdrawn  
  • Page 1

NCT ID: NCT02664571 Withdrawn - Alzheimer Disease Clinical Trials

Florbetaben as an Amyloid Plaque Marker in Elderly Patients With Focal or Disseminated Superficial Hemosiderosis

FBB ACC
Start date: July 2020
Phase: N/A
Study type: Interventional

The main objective of this study is to compare the distribution of Florbetaben (NEURACEQ: FBB) in the brain in amyloid cerebral angiopathy (ACA) manifested by isolated hemosiderosis in non-demented patients with that observed in healthy subjects, patients with ACA and with lobar hematoma(s) and patients with Alzheimer's dementia without MRI signs in favor of ACA.

NCT ID: NCT01991925 Withdrawn - Clinical trials for Hereditary Haemochromatosis

Implications for Quality of Life and Quality of Care in Patients With Hereditary Haemochromatosis

Start date: April 2016
Phase:
Study type: Observational

Patients with hereditary haemochromatosis will be interviewed/questioned about their Quality of life and the delivered quality of care in the hospital.

NCT ID: NCT01927913 Withdrawn - Metabolic Diseases Clinical Trials

Treatment of Iron Overload Requiring Chelation Therapy

Start date: November 20, 2014
Phase: Phase 2
Study type: Interventional

The purpose of this open-label study is to assess liver iron concentration using MRI imaging in subjects with beta-thalassemia when administered with either SPD602 or deferasirox for the treatment of chronic transfusional iron overload.

NCT ID: NCT01892644 Withdrawn - Clinical trials for Myelodysplastic Syndromes

Treatment of Iron Overload With Deferasirox (Exjade) in Hereditary Hemochromatosis and Myelodysplastic Syndrome

DefeHEMY
Start date: May 2013
Phase: Phase 2
Study type: Interventional

Hypothesis: Deferasirox can be used as a therapeutic agent to deplete the liver, heart and bone marrow of excess iron in patients with iron overload caused by myelodysplastic syndrome (MDS) and hemochromatosis (HC. Assess the effect of new serum biomarkers (NTBI and hepcidin) and MRI as indicators of iron overload and their usefulness to monitor iron depletion treatment. Study the effect of iron overload and iron depletion on intracellular signal transduction, trace metals concentrations in serum and urine and markers of oxidative stress in blood cells and urine.